Form 4: Stoke Therapeutics Executive Jonathan Allan Reports Stock Option and Restricted Stock Unit Grant
SEC Form 4 Filing
Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- On March 27, 2024, Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, reported the acquisition of 36,000 employee stock options with an exercise price of $14.17.
- These options vest monthly starting April 15, 2024, and expire on March 26, 2034.
- Allan also acquired 24,000 restricted stock units (RSUs) which vest annually beginning March 15, 2025.
- Each RSU represents one share of Stoke Therapeutics' common stock.
- Following these transactions, Allan directly owns 36,000 stock options and 24,000 RSUs.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, indicating standard executive compensation practices. It doesn't contain information that would significantly sway investor sentiment positively or negatively.
Positives
- The grant of stock options and RSUs to a key executive aligns their interests with those of the shareholders.
- The vesting schedules incentivize continued service to the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in the biotechnology industry.
- Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize similar equity-based compensation plans to incentivize their executives.
- The vesting schedules and grant sizes are generally aligned with industry norms for companies of Stoke Therapeutics' size and stage of development.
Stakeholder Impact
- The grant of equity-based compensation aligns the executive's interests with those of the shareholders, potentially driving long-term value creation.
- Employees may view the equity grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction for stock options and restricted stock units. |
| 04/15/2024 | First vesting date for the stock options (1/48th of the total award). |
| 03/26/2034 | Expiration date for the stock options. |
| 03/15/2025 | First vesting date for the restricted stock units (1/4th of the total award). |
| 03/15/2028 | Final vesting date for the restricted stock units. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.